MT-0814
/ Tanabe Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 30, 2020
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
(clinicaltrials.gov)
- P2; N=14; Terminated; Sponsor: Senju Pharmaceutical Co., Ltd.; N=35 ➔ 14; Recruiting ➔ Terminated; The study terminated for safety reasons
Clinical • Enrollment change • Trial termination • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Gene Therapies • Genetic Disorders • Macular Degeneration • Ophthalmology • Rare Diseases • Retinal Disorders
March 11, 2019
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
(clinicaltrials.gov)
- P2; N=35; Recruiting; Sponsor: Senju Pharmaceutical Co., Ltd.
Clinical • New P2 trial
March 11, 2019
Phase update
(clinicaltrials.gov)
- P1➔P2, Age-related macular degeneration
Phase shift
1 to 3
Of
3
Go to page
1